Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chip-CRC Trial: TROP2 CAR-NK Therapy + Cetuximab for Colorectal Cancer Peritoneal Carcinomatosis
NCT07411599Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Apr 2026
- Primary completion
- Nov 2028
- Modality
- Gene Editing, Gene Silencing, Lymphokine-Activated Killer Cells
- Countries
- 1
01
Overview
A Phase 2 trial of TROP2 CAR/IL-15 TGFBR2 KO NK cells in colorectal cancer (CRC), peritoneal carcinomatosis (PC), sponsored by University of Texas MD Anderson Cancer Center. Started Apr 2026; status: recruiting.
02
Drugs
TROP2 CAR/IL-15 TGFBR2 KO NK cells
03
Conditions
colorectal cancer (CRC)peritoneal carcinomatosis (PC)
Beyond the preview
Go deeper on NCT07411599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07411599.